HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Human Follicle Stimulating Hormone

A major gonadotropin secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and the LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. The alpha subunit is common in the three human pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.
Also Known As:
Follicle Stimulating Hormone, Human; Anthrogon; FSH, Human; FSH, human (follicle stimulating hormone); Human FSH; hFSH
Networked: 134 relevant articles (6 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Longobardi, Salvatore: 3 articles (12/2020 - 04/2013)
2. Balasch, J: 3 articles (03/2005 - 11/2000)
3. D'Hooghe, Thomas: 2 articles (12/2020 - 01/2019)
4. Hubbard, Julie: 2 articles (12/2020 - 01/2019)
5. Hero, Matti: 2 articles (01/2019 - 12/2018)
6. Huopio, Hanna: 2 articles (01/2019 - 12/2018)
7. Kohva, Ella: 2 articles (01/2019 - 12/2018)
8. Miettinen, Päivi J: 2 articles (01/2019 - 12/2018)
9. Raivio, Taneli: 2 articles (01/2019 - 12/2018)
10. Toppari, Jorma: 2 articles (12/2018 - 01/2002)

Related Diseases

1. Infertility (Sterility)
2. Hypogonadism (Hypergonadotropic Hypogonadism)
3. Anovulation
4. Ovarian Hyperstimulation Syndrome
01/01/2004 - "In recent years a number of publications have shown that chronic low-dose protocols are effective in reducing complications, in particular ovarian hyperstimulation syndrome (OHSS), especially if recombinant human follicle stimulating hormone (rhFSH) is used. "
12/01/2020 - "There is a risk for ovarian hyperstimulation syndrome (OHSS) with r-hFSH treatment, and an increased risk for thromboembolic events in the presence of pregnancy with OHSS. "
10/01/2006 - "Secondary outcomes included average initial and total recombinant hFSH dosage, serum E2 level on day of ovulation, number of oocytes retrieved, fertilization, number of top-quality embryos, endometrial thickness, implantation rate, pregnancy rate (PR), and incidence of ovarian hyperstimulation syndrome (OHSS). "
07/01/2003 - "Patients were randomly allocated on day 7 of stimulation to one of the two hCG administration criteria: [1] the E(2)-to-follicle > or =11 mm ratio was between 250 and 500 pmol/L/follicle and at least 2 follicles reached a mean diameter of 18 mm or [2] at least 2 follicles reached a mean diameter of 18 mm and the endometrium thickness was > or =8 mm. Duration and cumulative dose of recombinant human FSH, total number of growing follicles, oocytes retrieved, number and quality of embryos, pregnancy rates, and ovarian hyperstimulation syndrome (OHSS) rates. "
03/01/2000 - "There were seven cases (5.0%) of ovarian hyperstimulation syndrome in the r-hFSH group and three (2.2%), in the u-hFSH HP group (not significant). "
5. Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)

Related Drugs and Biologics

1. Menotropins (Humegon)
2. Gonadotropins
3. Luteinizing Hormone (Lutropin)
4. Estradiol (Delestrogen)
5. Hormones (Hormone)
6. Testosterone (Sustanon)
7. Clomiphene (Clomifene)
8. Prolactin
9. follitropin beta
10. Dehydroepiandrosterone (DHEA)

Related Therapies and Procedures

1. Hypophysectomy
2. Therapeutics
3. Injections
4. Immunotherapy
5. Drug Therapy (Chemotherapy)